apatinib

Phase 3Small molecule

LLaNova Medicines Zhejiang Co., Ltd.

apatinib is one of 554 small molecule programs targeting Gastric Adenocarcinoma. It is currently in Phase 3.

Indications

263

Total Trials

Active Trials

553

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric AdenocarcinomaRecruiting

Breast CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaTerminated

GlioblastomaActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

GC/GEJCRecruiting

Advanced Gastric CancerRecruiting

Locally Advanced Pancreatic CancerNot yet recruiting

Malignant AscitesRecruiting

Gastric AdenocarcinomaPhase 2

Recruiting

Breast CancerPhase 3

Active, not recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Terminated

GlioblastomaPreclinical

Active, not recruiting

Metastatic Prostate CancerPreclinical

Active, not recruiting

CholangiocarcinomaPreclinical

Active, not recruiting

GC/GEJCPhase 2

Recruiting

Advanced Gastric CancerPhase 2

Recruiting

Locally Advanced Pancreatic CancerPreclinical

Not yet recruiting

Malignant AscitesPhase 2

Recruiting

Showing 10 of 32 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Phase 3

16 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Spravato

WWim Janssens

Preclinical

2 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Duragesic

CCephalon

Preclinical

1 8

Vfend

PPrism Pharmaceuticals

Rilvegostomig

1 10

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Gastric Cancer

NCT06485271

Phase 2Not yet recruiting

First-Line Treatment

NCT06694324

Phase 2Recruiting

Breast Cancer

NCT05594095

Phase 2Not yet recruiting

Ovarian Carcinoma

NCT06081595

Phase 2Recruiting

Breast Cancer

NCT05447702

Phase 2Recruiting

Digestive System Cancer

NCT06099821

Clinical

Trials by Indication[1]

Gastric Cancer23 trials

Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT02525237·30 enrolled

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 3·NCT02537171·40 enrolled

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03472365·67 enrolled

Show 20 more trials

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2·NCT06693128·80 enrolled

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

Unknown status·HHebei Medical University·Phase 2·NCT03718624·36 enrolled

Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.

Unknown status·SSun Yat-sen University·Phase 2·NCT03144843·110 enrolled

HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer

Terminated·WWuhan University·N/A·NCT03349827·20 enrolled

A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer

Recruiting·—··NCT06485271·504 enrolled

Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer

Completed·FFudan University·Phase 2/3·NCT00970138·141 enrolled

Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer

Active, not recruiting·RRuijin Hospital·Phase 2/3·NCT04208347·580 enrolled

Study of the Apatinib Combine With POF Versus POF in Gastric Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT04121039·116 enrolled

A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer

Unknown status·—·Phase 2·NCT03271073·20 enrolled

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Completed·QQilu Hospital of Shandong University·Phase 2·NCT03878472·25 enrolled

A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer

Unknown status·SShanghai Zhongshan Hospital·Phase 2/3·NCT02409199·66 enrolled

Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer

Unknown status·DDongMa·N/A·NCT03255811·40 enrolled

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03813784·885 enrolled

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Unknown status·HHuazhong University of Science and Technology·Phase 3·NCT03598348·288 enrolled

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Recruiting·FFujian Cancer Hospital·Phase 2/3·NCT05699655·130 enrolled

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06385873·32 enrolled

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04267549·47 enrolled

The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02485015·80 enrolled

Apatinib for the Elderly Advanced Gastric Cancer

Completed·—·Phase 2·NCT03104283·48 enrolled

Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT01512745·267 enrolled

Breast Cancer15 trials

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting·WWest China Hospital·Phase 2·NCT05447702·35 enrolled

Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer

Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT07371910·200 enrolled

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Completed·FFudan University·Phase 2·NCT01653561·20 enrolled

Show 12 more trials

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Unknown status·HHebei Medical University Fourth Hospital·Phase 2/3·NCT03580395·200 enrolled

Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer

Completed·GGuangdong Provincial People's Hospital·Phase 2·NCT03243838·31 enrolled

Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer

Unknown status·HHebei Medical University Fourth Hospital·Phase 2·NCT03086785·120 enrolled

Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer

Unknown status·YYan Li·Phase 2·NCT03457467·30 enrolled

Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer

Recruiting·FFudan University·Phase 3·NCT06447623·184 enrolled

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04335006·80 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006)

Completed·PPeking University Cancer Hospital & Institute·Phase 2·NCT02878057·30 enrolled

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Recruiting·—·Phase 2·NCT06418594·30 enrolled

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02768415·40 enrolled

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

Recruiting·FFudan University·Phase 2·NCT05594095·620 enrolled

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 1·NCT03075462·98 enrolled

Hepatocellular Carcinoma15 trials

The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus

Unknown status·GGuangxi Medical University·Phase 2·NCT03520257·50 enrolled

SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT04014101·40 enrolled

Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma

Recruiting·NNanjing Tianyinshan Hospital·N/A·NCT06893887·300 enrolled

Show 12 more trials

Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03510416·22 enrolled

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03046979·30 enrolled

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Unknown status·TThe Affiliated Hospital of the Chinese Academy of Military Medical Sciences·Phase 1/2·NCT02942329·60 enrolled

Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03398122·248 enrolled

A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2/3·NCT07309419·222 enrolled

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Unknown status·PPeking University Cancer Hospital & Institute·Phase 1/2·NCT02727309·30 enrolled

Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02329860·400 enrolled

A Study of Apatinib in Patients With Advanced Hepatocellular Carcinoma

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01192971·121 enrolled

Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03114085·170 enrolled

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Not yet recruiting·ZZhujiang Hospital·Phase 2·NCT06546280·38 enrolled

SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06538935·80 enrolled

The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Unknown status·GGuangxi Medical University·Phase 2·NCT03511703·40 enrolled

Non-Small Cell Lung Cancer12 trials

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03777124·25 enrolled

Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung Cancer

Unknown status·—·Phase 2·NCT04506242·74 enrolled

A Study of Apatinib in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01270386·136 enrolled

Show 9 more trials

Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT02332512·417 enrolled

Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen

Withdrawn·XXinqiao Hospital of Chongqing·Phase 4·NCT03792503

Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients

Withdrawn·XXinqiao Hospital of Chongqing·Phase 2·NCT03190239

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Unknown status·—·Phase 2·NCT03416231·20 enrolled

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03083041·210 enrolled

Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01287962·480 enrolled

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

Not yet recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT07031154·43 enrolled

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy

Unknown status·WWuhan University·Phase 2·NCT04878107·88 enrolled

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT02780778·20 enrolled

Ovarian Cancer9 trials

Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer

Unknown status·YYang Zhijun·Phase 2·NCT03298074·60 enrolled

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04068974·28 enrolled

Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03942068·35 enrolled

Show 6 more trials

Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04383977·54 enrolled

Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy

Unknown status·—·Phase 2·NCT03547375·69 enrolled

Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer

Terminated·FFirst Affiliated Hospital of Harbin Medical University·Phase 2·NCT03587129·1 enrolled

Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03262545·60 enrolled

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02867956·35 enrolled

Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04000295·280 enrolled

64 more indications

Colorectal Cancer6 trials

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Unknown status·ZZhongshan Hospital Xiamen University·Phase 1/2·NCT04067986·62 enrolled

Apatinib in Refractory Colorectal Cancer

Completed·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03190616·54 enrolled

Apatinib for Resectable Colorectal Cancer

Withdrawn·—·N/A·NCT03228043

Show 3 more trials

mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer

Completed·HHuashan Hospital·Phase 3·NCT03365765·63 enrolled

Dose Finding and Pharmacokinetics/Pharmacodynamics Study of Apatinib in the Treatment of Advanced Colorectal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT01531777·40 enrolled

Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients

Unknown status·HHui ting Xu，MD·Phase 2·NCT03210064·42 enrolled

Small Cell Lung Cancer6 trials

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06786312·34 enrolled

Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

Unknown status·—·Phase 3·NCT03651219·90 enrolled

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Unknown status·TTianjin Medical University Second Hospital·Phase 1/2·NCT04659785·53 enrolled

Show 3 more trials

A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04453930·60 enrolled

A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer

Completed·TThe First Hospital of Jilin University·Phase 2·NCT03547804·31 enrolled

Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.

Completed·—·Phase 2·NCT02945852·40 enrolled

Camrelizumab5 trials

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Active, not recruiting·SSun Yat-sen University·Phase 3·NCT05198609·214 enrolled

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2·NCT05171309·35 enrolled

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

Unknown status·SSun Yat-sen University·Phase 2·NCT04454905·50 enrolled

Show 2 more trials

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04303741·46 enrolled

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

Unknown status·ZZhongda Hospital·N/A·NCT04559607·188 enrolled

Nasopharyngeal Carcinoma4 trials

Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma

Completed·SSichuan Cancer Hospital and Research Institute·Phase 2·NCT03180476·21 enrolled

Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04548271·25 enrolled

Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 2·NCT04547088·27 enrolled

Show 1 more trial

Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT03213587·51 enrolled

Glioma4 trials

Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas

Unknown status·TThe First Affiliated Hospital of Zhengzhou University··NCT04216550·600 enrolled

TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT

Unknown status·TThe Second Hospital of Hebei Medical University·Phase 2·NCT03741244·211 enrolled

A Study of Apatinib in Recurrent or Recurrent High-grade Glioma

Unknown status·WWest China Hospital·Phase 2·NCT03390062·30 enrolled

Show 1 more trial

Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas

Unknown status·WWuHui·Phase 2·NCT04253873·40 enrolled

Thyroid Cancer4 trials

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Recruiting·WWest China Hospital·Phase 2·NCT06482086·75 enrolled

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

Unknown status·PPeking Union Medical College Hospital·Phase 3·NCT03048877·118 enrolled

A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03199677·40 enrolled

Show 1 more trial

Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid Cancers

Unknown status·NNanjing First Hospital, Nanjing Medical University·Phase 2·NCT04180007·10 enrolled

Esophageal Cancer4 trials

An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2/3·NCT03285906·30 enrolled

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Unknown status·SShanghai Chest Hospital·Phase 2·NCT03913182·39 enrolled

A Study of Second-line Treatment of Postoperative Recurrence and Metastasis of Esophageal Cancer Treated With Apatinib

Withdrawn·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT03787251

Show 1 more trial

Apatinib for Metastatic Esophageal Cancer.

Unknown status·HHangzhou Cancer Hospital·Phase 2·NCT02544737·29 enrolled

Triple-Negative Breast Cancer4 trials

This Study Was a Prospective, One-arm Open Phase II Clinical Trial. A Systematic Review of the pCR of Apatinib in Combination With the Albumin Paclitaxel and Carboplatin Regimens for the Neoadjuvant Therapy of Triple-negative Breast Cancer, as Well as the Safety of Treatment

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT03650738·60 enrolled

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT03775928·80 enrolled

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03735082·29 enrolled

Show 1 more trial

Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients

Completed·FFudan University·Phase 2·NCT01176669·60 enrolled

Pancreatic Cancer4 trials

A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT02863367·30 enrolled

Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer

Unknown status·—·Phase 2·NCT03662035·30 enrolled

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

Unknown status·FFudan University·Phase 2·NCT04101929·126 enrolled

Show 1 more trial

Apatinib as Second-line Treatment of Advanced Pancreatic Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2·NCT02726854·30 enrolled

Chemotherapy4 trials

Apatinib Combined With Chemotherapy for NSCLC Patients Without T790M Mutation

Unknown status·TThe First Hospital of Jilin University·Phase 2·NCT03758677·30 enrolled

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Unknown status·TTianjin Medical University Cancer Institute and Hospital·N/A·NCT03671265·20 enrolled

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT03121846·80 enrolled

Show 1 more trial

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03092895·157 enrolled

Intrahepatic Cholangiocarcinoma3 trials

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03521219·30 enrolled

Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC

Recruiting·LLei ZHAO·Phase 2·NCT06296563·20 enrolled

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Completed·PPeking Union Medical College Hospital·Phase 2·NCT03251443·34 enrolled

First-line Treatment3 trials

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Unknown status·WWest China Hospital·Phase 1/2·NCT03201146·48 enrolled

APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC

Withdrawn·SSun Yat-sen University·Phase 2·NCT03164694

First-line Treatment of Advanced/unresectable DDLPS

Not yet recruiting·FFudan University·Phase 2·NCT06694324·49 enrolled

Osteosarcoma3 trials

Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy

Unknown status·RRuijin Hospital·Phase 2·NCT03742193·43 enrolled

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

Suspended·PPeking University People's Hospital·Phase 2·NCT04824352·44 enrolled

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Completed·GGUO WEI·Phase 2/3·NCT02711007·37 enrolled

Adenocarcinoma3 trials

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

Unknown status·SSir Run Run Shaw Hospital·Phase 1·NCT03071042·12 enrolled

A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction

Unknown status·HHebei Medical University·Phase 2·NCT03349866·48 enrolled

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Withdrawn·PPeking University·Phase 2·NCT04863430

Second-line Treatment3 trials

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

Unknown status·FFeng Wang·Phase 3·NCT05049681·234 enrolled

Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Unknown status·—·Phase 2·NCT03116555·37 enrolled

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03030937·74 enrolled

Esophageal Squamous Cell Carcinoma3 trials

Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed·FFudan University·Phase 2·NCT03274011·40 enrolled

Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06339619·32 enrolled

Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Unknown status·TThe First Affiliated Hospital of Zhengzhou University·Phase 2·NCT03193424·120 enrolled

Apatinib3 trials

Study of the Combination of Apatinib and POF

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03707639·26 enrolled

Phase I Study of the Combination of Apatinib and POF

Unknown status·FFujian Cancer Hospital·Phase 1·NCT03244774·18 enrolled

A Phase II Study of Apatinib in STS Patients

Unknown status·SShanghai Jiao Tong University Affiliated Sixth People's Hospital·Phase 2·NCT03064243·53 enrolled

Treatment3 trials

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Unknown status·SSichuan Cancer Hospital and Research Institute·Phase 1/2·NCT04133337·20 enrolled

Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT04126993·80 enrolled

SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT03417895·59 enrolled

Esophagus Cancer2 trials

Apatinib Treatment for Advanced Esophagus Cancer

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03170310·60 enrolled

Apatinib as First -Line Treatment for Advanced Esophagus Cancer

Unknown status·—·Phase 2·NCT03542422·50 enrolled

Cervical Cancer2 trials

Apatinib Treating Patients With Advanced Cervical Cancer After Radiotherapy and First-line Chemotherapy.

Unknown status·—·Phase 2·NCT03546855·69 enrolled

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Completed·SSun Yat-sen University·Phase 2·NCT03816553·45 enrolled

Non-squamous NSCLC2 trials

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

Unknown status·HHebei Medical University Fourth Hospital·N/A·NCT03634059·80 enrolled

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Unknown status·JJunling Li·Phase 2·NCT04670913·30 enrolled

Lung Adenocarcinoma2 trials

Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Unknown status·FFirst Affiliated Hospital of Kunming Medical University·Phase 2·NCT02704767·60 enrolled

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

Active, not recruiting·TThe First People's Hospital of Changzhou·Phase 2·NCT02493582·400 enrolled

Melanoma2 trials

Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT03383237·20 enrolled

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Unknown status·PPeking University Cancer Hospital & Institute·Phase 2·NCT03422445·30 enrolled

Adjuvant Therapy2 trials

Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection

Unknown status·SShanghai Zhongshan Hospital·Phase 2·NCT03261791·30 enrolled

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 2·NCT03609489·40 enrolled

Biliary Tract Cancer2 trials

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Completed·—·Phase 2·NCT04720131·28 enrolled

Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers

Unknown status·SSun Yat-sen University·Phase 2·NCT03144856·39 enrolled

Lung Cancer2 trials

A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Unknown status·SSun Yat-sen University·Phase 3·NCT02824458·246 enrolled

Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer

Unknown status·—·Phase 2·NCT02980809·60 enrolled

Carcinoma2 trials

Apatinib for Advanced Lung Squmamous Carcinoma

Unknown status·—·Phase 4·NCT03725423·50 enrolled

Apatinib for Advanced Biliary Carcinoma

Unknown status·FFudan University·Phase 2·NCT03427242·55 enrolled

Soft Tissue Sarcoma2 trials

Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial

Withdrawn·PPeking University People's Hospital·Phase 2·NCT03104335

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Unknown status·HHunan Cancer Hospital·Phase 2·NCT04239443·120 enrolled

Esophageal Squamous Cell Cancer2 trials

SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03603756·45 enrolled

Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

Unknown status·TThe First Affiliated Hospital of Anhui Medical University·Phase 2·NCT03224221·189 enrolled

Radiotherapy1 trial

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

Unknown status·UUnknown Sponsor·Phase 2·NCT03801200·90 enrolled

Unresectable Biliary Tract Carcinoma1 trial

Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06749730·63 enrolled

Liver Cancer1 trial

Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study

Unknown status·ZZhejiang Cancer Hospital·Phase 2/3·NCT02702323·40 enrolled

Unknown status·—·Phase 2·NCT02943252·30 enrolled

Angiogenesis1 trial

Study of Apatinib as an Inhibitor of Tumor Angiogenesis

Unknown status·FFudan University·Phase 1·NCT00633490·18 enrolled

Gastric Adenocarcinoma1 trial

XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma

Unknown status·—·Phase 1/2·NCT03599778·52 enrolled

Adverse Drug Reactions1 trial

Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations

Unknown status·SSun Yat-sen University·Phase 4·NCT03475589·217 enrolled

Gallbladder Carcinoma1 trial

Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma

Unknown status·—·Phase 2·NCT03702491·138 enrolled

Digestive System Cancer1 trial

KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 Blockade

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06099821·39 enrolled

Advanced1 trial

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07157969·300 enrolled

Glioblastoma1 trial

Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma

Unknown status·FFuzhou General Hospital··NCT03567135·60 enrolled

Pancreatic Carcinoma1 trial

The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04415385·48 enrolled

Locally Advanced1 trial

XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT03355612·456 enrolled

Metastatic Prostate Cancer1 trial

Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer

Completed·SSichuan Provincial People's Hospital·N/A·NCT02998242·40 enrolled

Oral Squamous Cell Carcinoma1 trial

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Completed·SShanghai Jiao Tong University School of Medicine·Phase 1·NCT04393506·21 enrolled

Neoadjuvant1 trial

Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients

Recruiting·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT05069857·46 enrolled

Ovarian Carcinoma1 trial

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

Not yet recruiting·JJin LI·Phase 2·NCT06081595·54 enrolled

Metastatic Cancer1 trial

A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer

Completed·EElevar Therapeutics·Phase 1·NCT03396211·30 enrolled

Non-Squamous1 trial

Apatinib in Advanced Non-squamous，NSCLC

Unknown status·JJian Fang··NCT03376191·100 enrolled

Patients With Advanced Solid Tumors1 trial

Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT03243643·80 enrolled

Lymphoma1 trial

Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma

Completed·ZZhengzhou University·Phase 4·NCT03376958·32 enrolled

PTCL1 trial

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Unknown status·RRuijin Hospital·Phase 1/2·NCT05559008·116 enrolled

Recurrent or Refractory1 trial

Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors

Completed·RRongjie Tao·Phase 2·NCT03660761·25 enrolled

Brain Injury1 trial

Effect and Safety of Apatinib on Radiation-Induced Brain Injury

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04152681·36 enrolled

Adrenal Cortical Carcinoma1 trial

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

Recruiting·WWest China Hospital·Phase 2·NCT06831175·28 enrolled

Adenoid Cystic Carcinoma1 trial

Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma

Unknown status·SShanghai Proton and Heavy Ion Center·Phase 2·NCT02942693·50 enrolled

Unresectable1 trial

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT05853172·30 enrolled

Advanced Solid Tumors1 trial

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT04569916·30 enrolled

Neuroendocrine Carcinoma1 trial

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Unknown status·HHuazhong University of Science and Technology·Phase 2·NCT05142865·30 enrolled

Metastatic Colorectal Cancer1 trial

Apatinib in the Treatment of Metastatic Colorectal Cancer

Unknown status·FFudan University·Phase 2·NCT03403452·33 enrolled

Advanced Malignancies1 trial

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

Terminated·UUniversity of Utah·Phase 1·NCT03407976·5 enrolled

Immunotherapy1 trial

A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC

Recruiting·GGrandPharma (China) Co., Ltd.·Phase 2·NCT07334483·120 enrolled

Chemoradiotherapy1 trial

Adebrelimab in Combination With Apatinib and Chemotherapy/Chemoradiotherapy in Immuno-experienced Second-line ESCC.

Not yet recruiting·TThe First Affiliated Hospital of Henan University of Science and Technology·Phase 2·NCT06464614·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 263 trial records for apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — LaNova Medicines Zhejiang Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: LLaNova Medicines Zhejiang Co., Ltd.

apatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Gastric Cancer23 trials

Breast Cancer15 trials

Hepatocellular Carcinoma15 trials

Non-Small Cell Lung Cancer12 trials

Ovarian Cancer9 trials

Colorectal Cancer6 trials

Small Cell Lung Cancer6 trials

Camrelizumab5 trials

Nasopharyngeal Carcinoma4 trials

Glioma4 trials

Thyroid Cancer4 trials

Esophageal Cancer4 trials

Triple-Negative Breast Cancer4 trials

Pancreatic Cancer4 trials

Chemotherapy4 trials

Intrahepatic Cholangiocarcinoma3 trials

First-line Treatment3 trials

Osteosarcoma3 trials

Adenocarcinoma3 trials

Second-line Treatment3 trials

Esophageal Squamous Cell Carcinoma3 trials

Apatinib3 trials

Treatment3 trials

Esophagus Cancer2 trials

Cervical Cancer2 trials

Non-squamous NSCLC2 trials

Lung Adenocarcinoma2 trials

Melanoma2 trials

Adjuvant Therapy2 trials

Biliary Tract Cancer2 trials

Lung Cancer2 trials

Carcinoma2 trials

Soft Tissue Sarcoma2 trials

Esophageal Squamous Cell Cancer2 trials

Radiotherapy1 trial

Unresectable Biliary Tract Carcinoma1 trial

Liver Cancer1 trial

Renal Cell Carcinoma1 trial

Cholangiocarcinoma1 trial

Head and Neck Cancer1 trial

Angiogenesis1 trial

Gastric Adenocarcinoma1 trial

Adverse Drug Reactions1 trial

Gallbladder Carcinoma1 trial

Digestive System Cancer1 trial

Advanced1 trial

Glioblastoma1 trial

Pancreatic Carcinoma1 trial

Locally Advanced1 trial

Metastatic Prostate Cancer1 trial

Oral Squamous Cell Carcinoma1 trial

Neoadjuvant1 trial

Ovarian Carcinoma1 trial

Metastatic Cancer1 trial

Non-Squamous1 trial

Patients With Advanced Solid Tumors1 trial

Lymphoma1 trial

PTCL1 trial

Recurrent or Refractory1 trial

Brain Injury1 trial

Adrenal Cortical Carcinoma1 trial

Adenoid Cystic Carcinoma1 trial

Unresectable1 trial

Advanced Solid Tumors1 trial

Neuroendocrine Carcinoma1 trial

Metastatic Colorectal Cancer1 trial

Advanced Malignancies1 trial

Immunotherapy1 trial

Chemoradiotherapy1 trial

References

Drug Info

Quick Facts

Related News